Independent Non-Executive Director & Senior Advisor
Biotech · Cardio-Metabolic Medicine · Obesity · Type 1 Diabetes · Microbiome
Turning scientific conviction into regulatory and commercial outcomes.
Board-level scientific, clinical and regulatory advice for biotech CEOs, boards and investors at asset-defining inflection points.
Discuss a board or advisory mandate →
Mandate Fit
Services
Mechanistic, clinical and regulatory assessment before licensing, financing or acquisition.
Trial design, endpoint strategy and evidence generation from early development to pivotal readout.
Preparation for FDA, EMA and advisory committee interactions where the label matters.
Independent scientific and clinical judgement for strategic company, asset and portfolio decisions.
Assessment of scientific credibility, clinical value, evidence requirements and investment priority.
Translation of complex science into credible investor, partner and board-level narratives.
Selectively available for NED and advisory mandates.
Discuss a board or advisory mandate →Track Record
As Chief Medical Officer and Chief Scientific Officer, led scientific, medical and regulatory strategy across a multi-billion-dollar evidence-based portfolio. Oversaw the clinical and regulatory programme for Aimmune / Palforzia (first FDA-approved peanut allergy treatment) and Seres / Vowst (first FDA-approved oral microbiome therapeutic). Conducted more than 50 scientific and clinical due diligences. Led global R&D integrations across acquisitions and partnerships.
As Global Vice President Medicine for Cardio-Renal-Metabolism, built and ran the entire franchise behind blockbusters such as Jardiance (empagliflozin) and Trajenta (linagliptin). The EMPA-REG OUTCOME trial was the first cardiovascular outcomes trial in diabetes to demonstrate a mortality benefit, establishing the first CV-mortality claim for an SGLT2 inhibitor, and was defended personally at FDA advisory committee hearings. He also argued the clinical value of both medicines in person before Germany’s Federal Joint Committee (G-BA), one of the world’s toughest pricing and reimbursement authorities. Few in Europe match this command of the global cardiovascular medicines market and its clinical development pathways.
Trained as a physician-scientist in endocrinology, diabetes and renal metabolism at LMU Munich, the University of Rochester and the University of Lausanne. Published more than 280 peer-reviewed papers with an h-index of 92. Conducted early mechanistic and clinical research in GLP-1, SGLT2 and metabolic disease that underpinned later programme development. Received Habilitation from LMU Munich in 2008.
Selective Current Mandates
Senior Advisor to the Board and CEO
First-in-class beta-cell regeneration therapy in Type 1 Diabetes.
Senior Advisor to the executive team
NLRP3 inflammasome inhibition at a Phase 2/3 clinical-development inflection point.
Companies we currently advise
Endorsements
"A rare combination of medical and business judgement, integrity, and a distinctive talent for developing others. He has left a lasting mark on NHSc and decisively strengthened its reputation as a leader in evidence-based nutrition and medical innovation."
"A unique combination of scientific rigour, strategic vision and the proven ability to bridge academia, clinical medicine and global industry. My highest recommendation for any senior leadership role in academia, industry or public health."
Contact
For board, advisory or investor diligence mandates, please contact directly.
Prof. Dr. med. Hans-Juergen Woerle
HJW Consulting Sàrl
Chemin des Colombaires 7